Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer

Table 1 Patient characteristics, survival and best response to treatment n (%)

Age (yr)	Median (62.2)	Range (32-84)
Sex	Male	Female
	67 (51.9)	62 (48.1)
BTC subtype	EHC	IHC	GBC	Total
	45 (34.9)	50 (38.8)	34 (26.4)	129
Stage	I	II	III	IV
	10 (7.8)	20 (15.5)	40 (31.0)	65 (50.4)
Grade	G1	G2	G3
	7 (5.4)	81 (62.8)	41 (31.8)
Treatment	BSC	Cx	Sx	Total
	56 (43.4)	64 (49.6)	9 (7.0)	129
Response to Cx	PR	SD	PD
	11 (17.2)	27 (42.2)	26 (40.6)
OS	BSC	Cx	Sx	All
(mo)	15.1	17.7	41.8	18.3

BSC: Best supportive care; Sx: Surgery; Cx: Chemotherapy; PR: Partial remission; SD: Stable disease; PD: Progressive disease; EHC: Extrahepatic BTC; IHC: Intrahepatic BTC; GBC: Gallbladder cancer.

Table 2 Inhibitor of differentiation protein expression and tumor characteristics n (%)

	Total (n)	IHC	EHC	GBC	Stage I	Stage II	Stage III	Stage IV	G1	G2	G33
ID1 neg	17	6 (5)	6 (5)	5 (4)	1 (1)	2 (2)	4 (3)	10 (8)	1 (1)	9 (7)	7 (5)
ID1 pos	112	44 (34)	39 (30)	29 (22)	9 (7)	18 (14)	30 (23)	55 (43)	6 (5)	72 (56)	34 (26)
ID2 neg	29	13 (10)	9 (7)	7 (5)	1 (1)	3 (2)	9 (7)	16 (12)	2 (2)	19 (15)	8 (6)
ID2 pos	100	37 (29)	36 (28)	27 (21)	9 (7)	17 (13)	25 (19)	49 (38)	5 (4)	62 (48)	33 (26)
ID3 neg	25	9 (7)	9 (7)	7 (5)	1 (1)	7 (5)	3 (2)	14 (11)	2 (2)	15 (12)	8 (6)
ID3 pos	104	41 (32)	36 (28)	27 (21)	9 (7)	13 (10)	31 (24)	51 (40)	5 (4)	66 (51)	33 (36)
ID4 neg	26	11 (9)	9 (7)	6 (5)	2 (2)	7 (6)	9 (7)	8 (7)	1 (1)	15 (12)	10 (8)
ID4 pos	96	35 (29)	35 (29)	26 (21)	8 (7)	13 (11)	23 (19)	52 (43)	6 (5)	61 (50)	29 (24)

EHC: Extrahepatic biliary tract cancer (BTC); IHC: Intrahepatic BTC; GBC: Gallbladder cancer; G: Grade.

Table 3 Multivariate analysis of clinical characteristics and inhibitor of differentiation protein expression

	ID1			ID2			ID3			ID4
	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value
Gender (male)	1.17	0.76-1.80	0.4717	1.07	0.71-1.64	0.7363	1.03	0.68-1.56	0.8877	1.29	0.82-2.02	0.267
IHC	0.57	0.33-0.97	0.0399	0.66	0.39-1.11	0.1193	0.72	0.42-1.23	0.2312	0.75	0.44-1.28	0.295
EHC	0.32	0.18-0.60	0.0003	0.36	0.20-0.64	0.0005	0.36	0.20-0.63	0.0003	0.32	0.18-0.57	0.0001
Stage III-IV	1.51	0.80-2.83	0.2037	1.5	0.80-2.80	0.2051	1.72	0.91-3.25	0.0928	1.24	0.65-2.35	0.5129
Grade 3	1.57	0.99-2.50	0.0532	1.58	1.01-2.47	0.0471	1.43	0.90-2.27	0.1326	1.53	0.96-2.45	0.0732
Surgery	0.3	0.17-0.55	< 0.0001	0.35	0.20-0.61	0.0003	0.33	0.18-0.61	0.0004	0.31	0.17-0.55	< 0.0001
Age	0.99	0.97-1.01	0.2327	0.99	0.97-1.01	0.3835	0.99	0.97-1.01	0.3118	0,99	0.97-1.02	0.6452
Response to Cx PD	0.81	0.44-1.47	0.4836	0.83	0.45-1.53	0.5442	0.65	0.35-1.20	0.1669	0.7	0.37-1.31	0.261
Response to Cx SD	0.4	0.22-0.71	0.002	0.4	0.22-0.72	0.0021	0.33	0.19-0.60	0.0002	0.37	0.20-0.67	0.0012
Response to Cx PR	0.43	0.20-0.91	0.0267	0.48	0.23-0.98	0.0426	0.46	0.22-0.94	0.0329	0.5	0.25-1.01	0.0531
Nuclear low	0.93	0.46-1.88	0.8447	1.41	0.80-2.50	0.2333	1.32	0.62-2.79	0.4721	0.94	0.38-2.33	0.8979
Nuclear high	1.2	0.65-2.20	0.5563	1.51	0.19-11.84	0.696	0.97	0.47-2.00	0.9275	0.63	0.27-1.47	0.2813
Cytoplasmic low	0.81	0.34-1.91	0.6276	0.59	0.07-4.80	0.6195	1.0	0.60-1.68	0.9948	0.68	0.45-1.04	0.0736
Cytoplasmic high	0.81	0.34-1.90	0.6261	0.64	0.08-5.04	0.6703	0.71	0.33-1.54	0.3866	0.31	0.03-2.85	0.3028

n = 129, number of events = 119, r² = 0.386 for ID1-3, r² = 0.392 for ID4; EHC: Extrahepatic biliary tract cancer (BTC); IHC: Intrahepatic BTC; Cx: Chemotherapy; PR: Partial remission; SD: Stable disease; PD: Progressive disease; ID: Inhibitor of differentiation.